The "Fast Money" traders weigh in on Eli Lilly and Juno Therapeutics, following failed drug trials.
Solanezumab, an experimental drug from Eli Lilly, failed to slow the loss of cognitive ability in patients with mild Alzheimer's disease.
Ronny Gal, Bernstein senior analyst, weighs in on Eli Lilly's failed Alzheimer's drug study results.
CNBC's Dominic Chu takes a look at some of the large cap S&P 500's biggest losers so far in 2016.
The “Fast Money Halftime Report” traders weigh in on the biotech sector, with Eli Lilly and Juno Therapeutics stocks dropping significantly.
Boris Schlossberg, Managing Director of FX Strategy, BK Asset Management, and Ari Wald, Oppenheimer, look at the post-election market surge.
U.S. stock closed mostly lower on Wednesday as earnings season continued, while solid economic data helped financials.
U.S. stock index futures pointed to a solidly lower open, as investors got ready to wade through another downpour of earnings.
Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
A new drug being tested slows Alzheimer's by removing plaque buildup in the brain. It's hope for millions suffering from the disease.
U.S. stocks steadied Wednesday, closing narrowly mixed after the Fed minutes affirmed previous expectations for a possible December rate hike.
Chris Raymond, Raymond James analyst, discusses how to trade the biotech sell-off amid election season.
CNBC took a deep look at stocks in one urban area that have produced big stock returns in a wide diversity of industries.
The "Fast Money" traders debated whether it's time to pile into the biotech sector after the sector gained 3 percent on Monday.
The "Fast Money" traders give you 5 trades in biotech.
Aside from the financial crisis, health care hasn't lagged the broader market this badly since Bill Clinton was president.
The "Fast Money Halftime Report" traders and Stephanie Link, TIAA Global Asset Management, take their positions on four stocks making news today, including Goodyear Tire, Mondelez and more.
With biotechs in the political crosshairs, is now the time to look at the space? With Michael Yee, RBC Capital biotech analyst.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
CNBC's Meg Tirrell reports the latest details on Valeant and its potential criminal probe. The "Fast Money Halftime Report" traders and Yana Barton, Eaton Vance portfolio manager, add perspective.